Amundi lifted its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 11.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 85,863 shares of the biotechnology company's stock after buying an additional 8,790 shares during the quarter. Amundi owned about 0.15% of Repligen worth $13,283,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Ballentine Partners LLC lifted its holdings in shares of Repligen by 4.0% during the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock worth $270,000 after buying an additional 72 shares in the last quarter. CIBC Asset Management Inc lifted its holdings in shares of Repligen by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock worth $246,000 after buying an additional 81 shares in the last quarter. MML Investors Services LLC lifted its holdings in shares of Repligen by 2.7% during the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company's stock worth $503,000 after buying an additional 89 shares in the last quarter. GAMMA Investing LLC raised its stake in Repligen by 15.2% in the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock valued at $98,000 after purchasing an additional 90 shares in the last quarter. Finally, Louisiana State Employees Retirement System raised its stake in Repligen by 0.7% in the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock valued at $2,087,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Repligen Trading Down 5.5 %
RGEN stock traded down $8.47 during trading on Tuesday, hitting $144.34. The company had a trading volume of 1,160,859 shares, compared to its average volume of 646,141. The business has a 50-day moving average of $157.16 and a 200-day moving average of $148.53. Repligen Co. has a one year low of $113.50 and a one year high of $200.23. The stock has a market cap of $8.09 billion, a PE ratio of -283.02, a PEG ratio of 4.54 and a beta of 0.95. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.
Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million for the quarter, compared to analysts' expectations of $167.58 million. Research analysts predict that Repligen Co. will post 1.72 earnings per share for the current fiscal year.
Insider Buying and Selling at Repligen
In other Repligen news, Director Margaret Pax purchased 250 shares of the company's stock in a transaction on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares in the company, valued at $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.20% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on RGEN. HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price target on shares of Repligen in a research note on Friday, February 21st. StockNews.com downgraded Repligen from a "hold" rating to a "sell" rating in a research note on Friday, February 21st. TD Cowen began coverage on Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 price target for the company. Evercore ISI began coverage on Repligen in a research note on Tuesday. They issued an "in-line" rating and a $155.00 price target for the company. Finally, JPMorgan Chase & Co. boosted their price target on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Repligen has a consensus rating of "Hold" and an average target price of $178.64.
Read Our Latest Stock Report on Repligen
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
See Also
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn how options trading can help you navigate market volatility, manage risk, and maximize returns with MarketBeat's "Unlock the Potential in Options Trading." Click the link below to have this special report delivered to your inbox.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
